Tim Osborne
Förmögenhet: 252 132 $ per 2026-05-31
Förmögenhet: 252 132 $ per 2026-05-31
Tim Osborne currently works at Forward Air Corp., as Executive Vice President-Operations from 2024.
Dr. Osborne also formerly worked at the University of California, Irvine, as Principal and Select BioVentures LLC, as Advisor.
Dr. Osborne received his undergraduate degree from King University.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
FORWARD AIR CORPORATION 0,08 % | 2026-03-15 | 23 831 ( 0,08 % ) | 252 132 $ | 2026-05-31 |
| Företag | Position | Start |
|---|---|---|
| FORWARD AIR CORPORATION | Verksamhetschef | 2024-01-01 |
| Företag | Position | Slut |
|---|---|---|
University of California, Irvine
University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Företagsledare/Principal | - |
Select BioVentures LLC
Select BioVentures LLC Investment ManagersFinance Select BioVentures focuses on investments in Florida-based and other bioscience companies. The firm seeks to invest in late pre-clinical and early clinical stage private or public biopharmaceutical, medical device and molecular diagnostic companies. | Privat kapitalinvesterare | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 4 |
|---|---|
Forward Air Corp.
Forward Air Corp. TruckingTransportation Provides less-than-truckload, final mile, truckload and intermodal drayage services | Transportation |
King University
King University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Select BioVentures LLC
Select BioVentures LLC Investment ManagersFinance Select BioVentures focuses on investments in Florida-based and other bioscience companies. The firm seeks to invest in late pre-clinical and early clinical stage private or public biopharmaceutical, medical device and molecular diagnostic companies. | Finance |
Välj din utgåva
All finansiell information anpassad till den nationella nivån